Weight gain profiles of new anti‐psychotics: public health consequences
Anti‐psychotic medications are an important therapeutic option for many individuals with
schizophrenia. Recently, a growing interest has been observed on weight gain, which is …
schizophrenia. Recently, a growing interest has been observed on weight gain, which is …
Clozapine's effects on body weight and resting metabolic rate: a case series
RM Procyshyn, A Chau, G Tse - Schizophrenia research, 2004 - Elsevier
The purpose of this pilot study is to determine if an association exists between clozapine-
associated weight gain and resting metabolic rate (RMR). In doing so, we used a “pretest …
associated weight gain and resting metabolic rate (RMR). In doing so, we used a “pretest …
The Association between Schizophrenia Clinical Severity and Obesity Risk: A Literature Review
I Li, J Hester - Journal of Student Research, 2021 - jsr.org
Obesity is a highly prevalent illness in schizophrenia patients. This review evaluates recent
literature on the relationship between obesity risk and schizophrenia psychopathology. Ten …
literature on the relationship between obesity risk and schizophrenia psychopathology. Ten …
Schizophrenia and obesity: impact of antipsychotic medications
DA Wirshing - Journal of Clinical Psychiatry, 2004 - psychiatrist.com
Obesity is an epidemic in this country and much of the rest of the developed world. It is a
major contributor to a range of metabolic disorders responsible for much of the medical …
major contributor to a range of metabolic disorders responsible for much of the medical …
Effect of clozapine on serum leptin, insulin levels, and body weight and composition in patients with schizophrenia
BB Kıvırcık, K Alptekin, S Çalışkan, A Çömlekçi… - Progress in Neuro …, 2003 - Elsevier
Objective: Weight gain frequently occurs during treatment with clozapine. However, the
pathophysiology of clozapine-induced weight gain remains unclear. The aim of this study …
pathophysiology of clozapine-induced weight gain remains unclear. The aim of this study …
[引用][C] Changes in Glucose and Cholesterol Level in Schizophrenic Patients Treated with Atypical Antipsychotics or with Valproate Combination
MD Doug-Hyun Han, MD Jung-Hyun Lee…
Mini-review: The relevance of body mass index and obesity in schizophrenia
This article was intended to mini-review some of the mechanistic aspects of obesity and
obesity-related metabolic disorders in schizophrenic patients, as well as the evidence re …
obesity-related metabolic disorders in schizophrenic patients, as well as the evidence re …
Prevalence of obesity in adolescent and young adult patients with and without schizophrenia and in relationship to antipsychotic medication
FM Theisen, A Linden, F Geller, H Schäfer… - Journal of psychiatric …, 2001 - Elsevier
The prevalence of obesity in inpatients of a German psychiatric rehabilitation center for
adolescents and young adults (mean age 19.5 years) is assessed and set into relationship …
adolescents and young adults (mean age 19.5 years) is assessed and set into relationship …
Obesity in schizophrenia: what can be done about it?
L Catapano, D Castle - Australasian Psychiatry, 2004 - journals.sagepub.com
Objective: To selectively review the literature on obesity in people with schizophrenia.
Conclusions: Obesity is a common problem for people with schizophrenia, with an estimated …
Conclusions: Obesity is a common problem for people with schizophrenia, with an estimated …
Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trial
K Mayfield, D Siskind, K Winckel, S Hollingworth… - BJPsych …, 2015 - cambridge.org
BackgroundClozapine causes significant metabolic disturbances including obesity and type
2 diabetes. Recent evidence that reduced glucagon-like-peptide-1 (GLP-1) may contribute …
2 diabetes. Recent evidence that reduced glucagon-like-peptide-1 (GLP-1) may contribute …